Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONYSE:CPSRNASDAQ:VKTXNASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$51.65+1.8%$41.36$17.86▼$58.40$4.12B-0.121.46 million shs906,981 shsCPSRCapstar Special Purpose Acquisition$24.01+0.0%$8.28$6.06▼$12.23$828.50M0.07556,189 shs6,454 shsVKTXViking Therapeutics$26.64+2.0%$25.76$18.92▼$81.73$2.99B0.754.18 million shs2.03 million shsZLABZai Lab$31.14-0.2%$31.03$16.01▼$39.77$3.44B1.04869,603 shs905,536 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.57%+9.43%+13.06%+13.92%+169.55%CPSRCapstar Special Purpose Acquisition0.00%+0.43%+1.01%+1.16%+267.64%VKTXViking Therapeutics-3.19%-3.19%-11.04%-7.01%-58.05%ZLABZai Lab+2.97%-0.42%+0.03%-8.26%+75.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.9385 of 5 stars3.53.00.04.72.11.70.0CPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics4.5451 of 5 stars4.52.00.04.72.53.30.0ZLABZai Lab2.7374 of 5 stars3.43.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5059.73% UpsideCPSRCapstar Special Purpose Acquisition 0.00N/AN/AN/AVKTXViking Therapeutics 3.00Buy$87.15227.10% UpsideZLABZai Lab 2.75Moderate Buy$47.3752.13% UpsideCurrent Analyst Ratings BreakdownLatest CPSR, AKRO, ZLAB, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/27/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/ACPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/A($1.18) per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/AZLABZai Lab$418.33M8.21N/AN/A$8.05 per share3.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$151.76M-$1.95N/AN/AN/AN/A-32.46%-29.83%8/8/2025 (Estimated)CPSRCapstar Special Purpose Acquisition-$15.30MN/A0.00∞N/AN/AN/AN/AN/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)ZLABZai Lab-$334.62M-$2.49N/AN/AN/A-76.14%-36.97%-27.10%8/5/2025 (Estimated)Latest CPSR, AKRO, ZLAB, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ACPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0517.2517.25CPSRCapstar Special Purpose AcquisitionN/A0.130.13VKTXViking TherapeuticsN/A36.4736.47ZLABZai LabN/A3.012.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ACPSRCapstar Special Purpose Acquisition64.87%VKTXViking Therapeutics76.03%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.94%CPSRCapstar Special Purpose AcquisitionN/AVKTXViking Therapeutics4.10%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million64.26 millionOptionableCPSRCapstar Special Purpose Acquisition234.50 millionN/ANot OptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionableZLABZai Lab1,950110.33 million94.24 millionOptionableCPSR, AKRO, ZLAB, and VKTX HeadlinesRecent News About These CompaniesSquarepoint Ops LLC Acquires Shares of 27,961 Zai Lab Limited (NASDAQ:ZLAB)June 3 at 3:57 AM | marketbeat.comLegacy Wealth Asset Management LLC Buys Shares of 22,285 Zai Lab Limited (NASDAQ:ZLAB)June 2 at 5:32 AM | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Short Interest Down 25.1% in MayJune 2 at 1:36 AM | americanbankingnews.comMillennium Management LLC Sells 15,023 Shares of Zai Lab Limited (NASDAQ:ZLAB)June 1 at 3:44 AM | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Sees Large Drop in Short InterestJune 1 at 2:43 AM | marketbeat.comZai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 TrialMay 31 at 8:48 PM | insidermonkey.comZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingMay 31 at 3:08 PM | businesswire.comZai Lab Announces Participation in Investor Conferences in June 2025May 30, 2025 | businesswire.comNorthern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 29, 2025 | marketbeat.comZai Lab Limited Is Well Positioned For Long-Term GrowthMay 28, 2025 | seekingalpha.comZai Lab Limited Is Well Positioned For Long-Term GrowthMay 28, 2025 | seekingalpha.comBNP Paribas Financial Markets Purchases 18,472 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 26, 2025 | marketbeat.comTwinbeech Capital LP Buys Shares of 27,039 Zai Lab Limited (NASDAQ:ZLAB)May 24, 2025 | marketbeat.comZai Lab Limited: Banking On Chinese Pharma GrowthMay 22, 2025 | seekingalpha.comWoodline Partners LP Has $46.09 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases 270,136 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 22, 2025 | marketbeat.com43,178 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Lazard Asset Management LLCMay 22, 2025 | marketbeat.comVestal Point Capital LP Invests $7.86 Million in Zai Lab Limited (NASDAQ:ZLAB)May 21, 2025 | marketbeat.comZai Lab gets FDA fast track status for lung cancer treatmentMay 19, 2025 | msn.comRTW Investments LP Takes Position in Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 233,103 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPSR, AKRO, ZLAB, and VKTX Company DescriptionsAkero Therapeutics NASDAQ:AKRO$51.65 +0.92 (+1.81%) Closing price 03:59 PM EasternExtended Trading$51.68 +0.02 (+0.05%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Capstar Special Purpose Acquisition NYSE:CPSRCapstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.Viking Therapeutics NASDAQ:VKTX$26.64 +0.52 (+2.01%) Closing price 03:59 PM EasternExtended Trading$26.60 -0.04 (-0.15%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Zai Lab NASDAQ:ZLAB$31.14 -0.05 (-0.17%) Closing price 03:59 PM EasternExtended Trading$31.10 -0.03 (-0.10%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
